|
ADA
Jun 24, 2018 9:50:49 GMT -5
chc likes this
Post by porkini on Jun 24, 2018 9:50:49 GMT -5
Sayhey, I can actually now follow what you are saying clearly now. This is really great! 🎯 Speaking of obsolete, it appears to me Agedhippie might now be obsolete. 😆 Brother - its been a long road and I am glad what I have been saying for years is now being understood and was demonstrated in an "Official, Peer Reviewed Study". One thing for sure, I am damn glad Dr. Kendall is there, could interrupt the results and present them in plain English and then put out the press release they did.
As far as Aged, we love Aged. While soft bashing afrezza for years, he/she has always been respectful and I for one always like a good challenge. Who is obsoleted are Aged's endos who 3+ years ago said afrezza would make your lungs explode and they are still teaching people the medically incorrect way to adjust their baseline.
Maybe now Aged will give afrezza a go, at least for the corrections. What I would now like to see is an "Official" study showing afrezza's use for corrections. How great would those results be?
Big "maybe"? It has been just over "a couple of years" now... I won't hold my breathe on this one quite yet.
|
|
|
Post by oldfishtowner on Jun 24, 2018 12:39:24 GMT -5
Presenter for the hypoglycemia paper: Lawrence Blonde, MD
Biography Dr. Blonde graduated from Albany Medical College in New York, where also completed his internship, residency and endocrinology fellowship. He is board certified in internal medicine, nuclear medicine, and endocrinology and has been on staff at Ochsner since 1974. Among his many other professional responsibilities, Dr. Blonde serves as Director of the Ochsner Diabetes Clinical Research Unit, and is an Associate of Internal Medicine Residency Program Director. Dr. Blonde is chair of the Steering Committee of National Diabetes Education Program (NDEP), a partnership of the National Institutes of Health, the Centers for Disease Control and Prevention, and more than 200 public and private organizations working to "change the way diabetes is treated." He is also a member of the Board of Directors of the American Association of Clinical Endocrinologists (AACE). www.ochsner.org/doctors/lawrence-blonde/#overview
|
|
|
Post by sportsrancho on Jun 24, 2018 17:13:44 GMT -5
|
|
|
Post by sportsrancho on Jun 25, 2018 7:01:58 GMT -5
|
|
|
Post by peppy on Jun 25, 2018 7:08:15 GMT -5
STAT Study Oral Presentation Highlights Title: Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin (TI) in Patients with Type 1 Diabetes on Multiple Daily Injections: STAT Study Presenter: Satish Garg, M.D. Highlights: Compared to insulin aspart, the per-protocol use of Afrezza (i.e., with supplemental doses 1 and/or 2 hours post-meal): • Significantly lowered PPG values at 1 and 2 hours after meals (-38.2 and -17.9 mg/dl, respectively) as measured by CGM • Significantly reduced overall PPG excursions (i.e., the peak increase in CGM glucose during the 1-4 hour post-meal period) by 15%. In addition, o a 15% reduction in overall PPG excursions was also seen in Afrezza subjects who dosed at mealtimes only and did not follow the supplemental dosing protocol o PPG excursions were significantly reduced following breakfast (approximately 20%) and lunch (approximately 25%) (based on an analysis of all subjects in the Afrezza group without regard to their adherence to the supplemental dosing protocol) • Significantly improved all-day glucose time-in-range by an average of 1.5 hours, or 12% Conclusion: Afrezza may provide greater improvement in PPG control than insulin aspart “I am very pleased to have led the novel STAT trial, performed as a collaborative trial with several other investigators at the Barbara Davis Diabetes Center as well as four other sites around the country. This study shows that the use of Afrezza at mealtimes, and as needed following meals, provides significant improvement in postprandial glucose (PPG) when compared to mealtime insulin aspart in Type 1 diabetes patients who are using continuous glucose monitoring,” stated Halis Kaan Akturk, M.D., Assistant Professor of Medicine and Pediatrics, Barbara Davis Center for Diabetes, University of Colorado Denver and the principal investigator of the STAT study. “These new data presented at the ADA’s 78th Scientific Sessions significantly advance our understanding of the potential clinical benefits of Afrezza for those living with Type 1 diabetes,” stated Michael Castagna, Chief Executive Officer of MannKind. “We believe the last frontier for driving better outcomes for people living with diabetes is the ability to control mealtime glucose levels. Based on the data generated to date, we believe that Afrezza – with its ability to lower HbA1c levels without the same degree of concomitant risk of hypoglycemia as other mealtime insulins – has the potential to be the treatment of choice for those individuals with diabetes requiring mealtime glucose control.”
|
|
|
Post by mnholdem on Jun 25, 2018 7:17:29 GMT -5
20%-25% reduction WITHOUT REGARD to adherence to the dosing protocol. That is impressive.
|
|
|
Post by sportsrancho on Jun 25, 2018 11:19:29 GMT -5
|
|
|
Post by sportsrancho on Jun 25, 2018 11:21:25 GMT -5
|
|
|
Post by sportsrancho on Jun 25, 2018 11:54:52 GMT -5
|
|
|
Post by sportsrancho on Jun 25, 2018 11:58:20 GMT -5
|
|
|
Post by sayhey24 on Jun 25, 2018 12:09:17 GMT -5
Sports - you should tweet to take the afrezza and have no hypos as a T2 and maybe stop the progression.
|
|
|
Post by harryx1 on Jun 25, 2018 12:18:41 GMT -5
|
|
|
Post by babaoriley on Jun 25, 2018 12:20:19 GMT -5
Re CMO's in general - this is from another company I'm in (loser), and this was meant to level criticism at the company in terms of being able to attract the right CMO (it was written by a sharp guy, so obviously, not me):
"No self respecting CMO would join _____. Quality CMOs are in big demand, especially if they have taken a drug all the way through to approval. What would a CMO think when he arrived at the US location two floors above a massage parlor? Top CMOs are rock stars. Their image is very important to their position in the industry. What would a candidate CMO think upon learning the future of _____ was based upon retrospective (slice and dice) statistical findings? I think for the time being ____ is better off without a CMO."
So happy we have our rockstar!!
|
|
|
Post by sayhey24 on Jun 25, 2018 12:23:32 GMT -5
Too funny - twitter.com/SanofiDCV"There is a need for a treatment option that addresses #cardiovascular risk factors as well as improving ‘Time in Range’ and HbA1c." Someone call Brandicourt and send him the MNKD press release.
|
|
|
Post by brotherm1 on Jun 25, 2018 12:49:53 GMT -5
wow. The importance of time in range is suddenly now being mentioned by MiniMed and now SNY.
|
|